PCV78 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN AN AUSTRIAN SETTING  by Schwarz, B & Wild, R
13th Euro Abstracts A355
hydrochlorothiazide. Using the ACCOMPLISH results for valsartan/amlodipine, it is 
likely to have reasonably low costs per event avoided for the treatment of high risk 
patients with hypertension in Sweden.
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ONE-YEAR COST-EFFECTIVENESS OF CYTOCHROME P450 2C19 
GENOTYPE-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH 
ACUTE CORONARY SYNDROMES IN THE UNITED KINGDOM
Charland SL1, Agatep B1, Malone D2, Stanek E1
1Medco Health Services, Inc., Bethesda, MD, USA; 2University of Arizona, Tucson, AZ, USA
OBJECTIVES: Cytochrome P450 2C19 (CYP2C19) genotype has been shown to 
affect cardiovascular (CV) outcomes for clopidogrel but not prasugrel. This study 
evaluates the incremental cost-effectiveness ratio (ICER) of CYP2C19-guided vs. 
routine antiplatelet therapy in acute coronary syndrome (ACS) patients in the UK. 
METHODS: We constructed a literature-based, decision analytic, Markov model to 
estimate the annual cost-effectiveness of CYP2C19-guided aspirin plus either clopido-
grel or prasugrel therapy vs. no genotyping. Post-initial ACS CV events were based 
on the TRITON-TIMI 38 study and genetic substudy. Cost data sources were: 
National Health Service (NHS) reference cost for 2008–09—nonfatal MI and stroke, 
CV death, intracranial hemorrhage, other life-threatening bleed, and minor bleed; 
Drug Tariff 2009—drugs; www.genetic-health.co.uk/—CYP2C19 genotyping; or US-
based reference pricing converted to £ using appropriate exchange rates -monthly CV 
disease maintenance cost. Disease-state utilities were obtained from published sources. 
The model allowed for clopidogrel/prasugrel discontinuation and aspirin monother-
apy. Model sensitivity was assessed using 1-way analysis of parameters varied by 
quartile or at least +/− 25%. RESULTS: The analysis demonstrated an increase in 
incremental cost (£81); greater incremental QALY (0.05); and an ICER £1529/QALY 
for CYP2C19 genotype-guided therapy over 12 months. The model was most sensitive 
to monthly CV care cost, NFMI cost, proportion of patients on clopidogrel, and life-
threatening bleeding cost. The model was least sensitive to the cost of clopidogrel, 
prasugrel, or CYP2C19 genotyping. CONCLUSIONS: The model-based ICER of 
£1,529/QALY for the CYP2C19 testing strategy is signiﬁ cantly less than the UK 
threshold of £20,000 that is considered good value. CYP2C19 genotype-guided clopi-
dogrel or prasugrel therapy is cost-effective for up to 1 year in ACS patients in the 
UK.
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CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE 
VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH 
PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION
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OBJECTIVES: Dronedarone is a novel anti-arrhythmic drug (AAD) that, unlike other 
AADs, was shown to reduce cardiovascular hospitalizations or death in the ATHENA 
clinical trial. In addition, dronedarone reduces AF recurrence, maintains rate control, 
and has a favorable safety proﬁ le with low pro-arrhythmic and organ-toxicity proﬁ le. 
The objective of this study was to construct a health economic model to assess the 
cost-effectiveness of dronedarone vs. other AADs in a Canadian setting. METHODS: 
A state transition model evaluated through patient-level simulation has been developed 
using Microsoft Excel. It allows comparisons over varying time horizons and treat-
ment durations, and consists of health states for: treatment, off treatment, symptom-
atic AF recurrences, stroke, acute coronary syndromes, coronary heart failure and 
death. Transition probabilities were derived from the patient level data from the 
ATHENA trial, and relative risks between dronedarone and three commonly used 
comparators (amiodarone, sotalol and ﬂ ecainide) identiﬁ ed by clinical experts were 
derived from a mixed treatment comparison (systematic review) of published clinical 
trials published between 1980 and 2009. Patients discontinuing treatments were 
assumed to progress according to the rates in the standard of care arm of ATHENA. 
Costs of monitoring and initiation were taken into account. Costs were applied to 
each adverse event (AE) observed (Canadian Costs [C$] 2007). Effectiveness was 
expressed as QALYs, using preference based utility weights for health states based on 
published data. Discounting was 5% and a lifetime horizon was taken. RESULTS: 
The model predicts higher quality adjusted survival for patients on dronedarone: 
between 1.13 and 2.01 QALYs depending on comparator. In Canada, the resulting 
ICERs (per QALY) are C$5600 compared to amiodarone, C$5300 compared to ﬂ e-
cainide, and C$5300 compared to sotalol. Results were sensitive to differences in risk 
of mortality between treatment groups. CONCLUSIONS: Dronedarone represents a 
cost-effective treatment for patients with atrial ﬁ brillation in Canada.
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OBJECTIVES: To perform a cost-effectiveness analysis (CEA) for the use of droneda-
rone in patients with atrial ﬁ brillation (AF) in order to prevent hospitalizations due 
to cardiovascular events or death (HCED), from the public health care system perspec-
tive in Mexico. METHODS: A CEA was made based on the clinical information from 
the multicenter, randomized, clinical study ATHENA, where dronedarone was com-
pared to placebo on top of standard treatment in patients with AF. Overall, 2301 
patients were randomized to dronedarone, and 2327 to placebo. The primary clinical 
endpoint was HCED. Only direct medical health care costs were calculated. The health 
resource utilization was elicited from the ATHENA trial. The unit costs of each event 
were obtained from the medical literature and/or validated by local experts, whenever 
information was not available. Most of the cost information is based on IMSS (Social 
Security) ﬁ gures, and updated to year 2009 (1c = MX$17.05). a discount rate of 5% 
was used. An incremental cost-effectiveness analysis was performed complemented by 
a deterministic sensitivity analysis (DSA) to assess robustness of the model. RESULTS: 
Patients randomized to dronedarone experienced 1190 events of HCED (average rate 
0.51 [CI 95%: 0.47–0.55]) while patients in the placebo group had 1601 (average 
rate 0.69 [CI 95%: 0.64–0.74]), or −415 events, 18% less hospitalizations (CI 95%: 
12–25%) for the dronedarone group. The average cost per patient in the dronedarone 
group was c3028 as compared to the placebo group of c2,941, yielding a cost differ-
ence of c87.4, and an avoided incremental cost per HCED of c477.00 of dronedarone 
vs. the placebo group. The DSA shows the analysis is robust. CONCLUSIONS: 
According to the ATHENA trial, dronedarone is a cost-effective treatment option for 
the reduction of HCED from the Mexican perspective. Dronedarone’s value could be 
enhanced if indirect costs averted from the decreased rates of HCED included.
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Darba J1, Restovic G2, Kaskens L2, Tunceli K3, Plans P4
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain; 3Merck, 
Whitehouse Station, NJ, USA; 4Generalitat de Catalunya, Barcelona, Spain
OBJECTIVES: The aim of this study is to estimate cost-effectiveness of lowering low-
density lipoprotein cholesterol (LDL-C) with statin monotherapy in patients with 
elevated LDL-C with two or more cardiovascular risk factors or either coronary heart 
disease (CHD) in Spain. METHODS: A Markov model was developed to represent 
the transition of a cohort of patients with elevated LDL-C or with CHD at risk of a 
cardiovascular event (CVE) through four health states: patients with LDL-C, CVE, 
death by CVE and death by other causes. Probabilities of a CVE in females and males 
were determined, based on CHD risks estimated trough locally-adjusted Framingham 
risk equations using data from the DORICA and PRIMULA study. LDL-C lowering 
efﬁ cacy of statins, mortality, and health-state utilities were obtained from published 
scientiﬁ c literature. Cardiovascular risk factors included were age, systolic blood pres-
sure, diabetes, smoking and high-density lipoprotein cholesterol (HDL-C). Treatment 
and CVE direct medical costs were obtained from a medication database and DRGs 
for public hospitals in 2009 in Spain. Deterministic results were estimated and a 
probabilistic sensitivity analysis was conducted. Results were expressed as expected 
cost per quality adjusted life-years (QALYs) gained. RESULTS: In deterministic analy-
ses, expected costs per patient per year at age of 40 were higher for patients with 2 
or more cardiovascular risk factors who were not treated than those who were treated 
(female: c41,300 vs. c40,106; male: c22,160 vs. c18,333). Effectiveness was higher 
for treated patients in both genders (female: 0.17 QALY; male: 0.37 QALY). Similar 
results were found for patients with CHD (female: c35,706 vs. c34,664, 0.10 QALY; 
male: c16,892 vs. c16,073, 0.12 QALY). CONCLUSIONS: From the perspective of 
the Spanish health care system, treatment with statin monotherapy is considered to 
be cost-effective versus no treatment in female and male patients with 2 or more risk 
factors or CHD.
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OBJECTIVES: High resting heart rate (HR) has been progressively accepted as a 
modiﬁ able cardiovascular risk factor. Ivabradine (ProcoralanÒ) is a speciﬁ c HR lower-
ing agent. This study aimed estimating the cost-effectiveness of ivabradine in stable 
angina patients with a normal sinus rhythm and a resting HR above 70 beats per 
minute (bpm) from the Austrian health care perspective: 1) versus generic diltiazem 
when beta-blockers (BB) are contra-indicated or non tolerated; and 2) in combination 
with generic atenolol versus generic atenolol alone. METHODS: A Markov chain 
Monte Carlo stochastic simulation model was used to estimate the inﬂ uence of HR 
lowering in cardiovascular morbidity and mortality and its economic consequences. 
Treatments considered are ivabradine, 7.5 mg twice a day, diltiazem, 240 mg once a 
day and atenolol 50 mg once a day. HR distribution, survival and time to hospitaliza-
tion were modelled as weibull functions. Events considered were acute myocardial 
infarction, stroke, heart failure, death and revascularization procedures. Only direct 
medical costs were included. Effectiveness was measured in quality-adjusted life-years 
(QALYs). Time horizon was set at 20 years and discount rates for costs and effective-
ness were 3%/year. RESULTS: The between-group difference in HR reduction was 
−6.4 bpm and −8.8 bpm in favour of ivabradine strategy in targeted patient popula-
tions 1) and 2) respectively. Incremental ivabradine strategy cost was c6789 versus 
generic diltiazem and c6749 versus generic atenolol. Incremental QALYs were 1.067 
and 1.076 respectively. Incremental cost-effectiveness ratios for ivabradine strategy 
were c5800/QALY and c6273/QALY. Deterministic sensitivity analyses showed that 
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ivabradine strategy is cost-effective in both approaches in all cases at a willingness to 
pay threshold of c22,000/QALY. CONCLUSIONS: In an Austrian setting, ivabradine 
is a cost-effective treatment in stable angina patients with resting HR > 70 bpm.
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OBJECTIVES: Atrial ﬁ brillation (AF) contributes for stroke, sudden death, heart 
failure, markedly reduced exercise capacity and degraded quality of life. Therefore, 
an effective treatment of AF is expected to reduce cardiovascular (CV) events and their 
costs. In 2010, dronedarone has been approved by Korean FDA for risk reduction of 
CV hospitalization in patients who are in sinus rhythm or who will be cardioverted 
with relevant conditions. The purpose of this study is to evaluate the cost-effectiveness 
of dronedarone compared with amiodarone in Korea. METHODS: We used the 
Markov simulation model for AF patients consisting with health states for AF treat-
ment, off-AF treatment, symptomatic AF recurrences, stroke, acute coronary syn-
dromes, congestive heart failure and death. Transitional probability was obtained 
from ATHENA trial and published literatures. Patient baseline, drug cost, initiation 
and monitoring cost of AF treatment, disease state cost and adverse event cost were 
obtained from national insurance claim database. The effectiveness of amiodarone vs. 
dronedarone was drawn from results of mixed treatment comparison. Discount rate 
for cost and effectiveness were applied as 5%. From the societal perspectives, we 
evaluated cost for life-year gained (LYG) and quality adjusted life-years (QALYs) until 
patients become 100 years old. Subgroup analysis and sensitivity analysis was per-
formed to deal with uncertainty. RESULTS: In the base-case analysis, the incremental 
cost-effectiveness ratio (ICER) of dronedarone versus Amiodarone was approximately 
c2344/LYG (KRW 3.75 million, 1 Euro = 1600 KRW). Results were robust across 
subgroups. The ranges of ICER in the sensitivity analysis were from around c1875 ~ 
c3750/LYG (KRW 3 to 6 million/LYG). Fifty percent of simulations in probabilistic 
sensitivity analysis fall below a willingness-to-pay of about c3750 per QALYs (KRW 
6 million per QALYs). CONCLUSIONS: These results showed that dronedarone is 
to be cost-effective vs. amiodarone for AF patients in Korea.
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PLACEBO FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN 
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OBJECTIVES: Antihypertensive therapy is a well-established approach to reducing 
the risk of cardiovascular disease (CVD). Amlodipine besylate, a calcium channel 
blocker, has been shown to be an effective antihypertensive agent. The objective of 
this study was to evaluate the cost-effectiveness of antihypertensive therapy with 
amlodipine besylate for the prevention of CVD in Korea from a health care perspective 
over a lifetime. METHODS: To estimate long-term cost and effects, a Markov model 
consisting of nine health states was constructed: Healthy with hypertension, Angina, 
Myocardial Infarction (MI), Post-MI, Stroke, Post-stroke, CHD death, CVD death, 
non-CVD cause death. One health state to another can occur with a certain probability 
at yearly intervals. The incidence of CVD was obtained from published local sources, 
whereas the risk reductions associated with antihypertensive therapy were taken from 
the medical literature, selected studies randomly assigned amlodipine besylate or 
placebo and followed up for at least 1 year. Utility values for CVD and costs of 
amlodipine besylate were drawn from published literature based on 2005 Korea 
National Health and Nutritional Examination Survey (KNHANES) data, and Korean 
pharmaceutical pricing lists, respectively. Costs for CVD were found in published 
cost-of-illness studies based on local hospital charge data. Patient outcomes were 
modeled for 45 years, and incremental cost-effectiveness ratios were calculated for 
amlodipine besylate compared with placebo. RESULTS: For a 55-year-old patient 
with hypertension, the incremental cost of amlodipine besylate compared with placebo 
was 3,213,660 Korean won (KW) per patient, although the incremental effectiveness 
of amlodipine besylate was 0.210 quality-adjusted life-years (QALYs) gained per 
patient. Therefore, the incremental cost-effectiveness ratios associated with amlodipine 
besylate were 15,288,941 KW/QALY, compared to no treatment. Sensitivity analyses 
indicated these results to be robust. CONCLUSIONS: The results from the model 
indicate that amlodipine besylate provides a cost-effective antihypertensive treatment 
strategy for the prevention of CVD in Korea.
PCV81
THE COMPARATIVE ANALYSIS OF THE EFFECTIVENESS AND THE 
COSTS OF USING THE LOW-MOLECULAR-WEIGHT HEPARINS AND 
THE ORAL ANTICOAGULANTS FOR THE TREATMENT OF THE 
VENOUS THROMBOEMBOLISM IN POLAND
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OBJECTIVES: The currently recommended standard treatment of the venous throm-
boembolism (VTE) are the oral anticoagulants (OA) in the majority of patients and 
the low-molecular-weight heparins (LMWH) in the selected subpopulations. The 
titration of the OA doses is difﬁ cult and often ineffective. The goal of this research 
was to compare the OA and the LMWH in the VTE treatment in terms of effectiveness, 
safety and cost-effectiveness. METHODS: The systematic review of the scientiﬁ c lit-
erature comparing the VTE treatment with OA and LMWH was performed. Among 
others, the resources of the Cochrane Library, the MEDLINE, the Embase and the 
Biomed Central were searched. The metaanalysis of the reported treatment outcomes 
was performed using the RevMan5® software. The cost analysis and the cost-effec-
tiveness analysis were performed. The data on the costs of treatment of the VTE in 
Poland were collected through the retrospective review of patient records obtained 
from the three hospitals and the anticoagulation clinic in the Krakow area, the phar-
maceutical reimbursement databases and the public payer’s charge tariffs for the 
medical services. The modeling (decision tree) was performed using the TreeAge-
Pro2009® software. RESULTS: The most important differences between the OA and 
the LMWH were related to the better prevention of the VTE incidence and the better 
prevention of the small bleedings. With respect to none of the assessed outcomes the 
OA were better than the LMWH. Within a six month treatment period the Incremental 
Cost-Effectiveness Ratio of avoiding the complication incidents was 49,865 zlotys 
(c12,242) from the payer perspective and 3,609 zlotys (c887) from the patient perspec-
tive. CONCLUSIONS: The LMWH offer the better effectiveness and safety than the 
OA but their cost-effectiveness is still limited by the relatively high prices of the 
LMWH.
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MAKERS—THE CASE OF SWEDISH NATIONAL GUIDELINES FOR 
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Eckard N1, Janzon M2, Levin LÅ1
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OBJECTIVES: Despite the continuing interest in health economic research, we could 
ﬁ nd no comprehensive and accessible data set on costs and effects, useful as practical 
information for decision makers who must allocate scarce resources within the car-
diovascular ﬁ eld. The objective of this study was to present the cost-effectiveness 
league table, used in the Swedish national guidelines for heart disease and highlight 
issues of importance when communicating and interpreting cost-effectiveness evidence 
to decision makers. METHODS: A unique systematic literature search for the treat-
ment of heart diseases was conducted. We then compiled all available cost-effective-
ness ratios for different heart conditions and treatment strategies, in a so called league 
table. All cost-effectiveness results were expressed as a cost per quality adjusted life-
years (QALY) or life-year gained. The league table was broken down to illustrate how 
health economic results may be communicated and made accessible to decision 
makers. We have highlighted methodological issues when interpreting cost-effective-
ness league tables by using implantable cardioverter deﬁ brillators (ICDs) as an 
example. RESULTS: More than 200 cost-effectiveness ratios were found and compiled 
in the league table ranging from dominant to c950,000 per QALY. Using ICD as an 
example we identiﬁ ed various problems when interpreting league table results. The 
results are context speciﬁ c, time dependant, comparator dependent, often based on 
point-estimates giving a false sense of precision. CONCLUSIONS: League tables 
provide a means of presenting cost-effectiveness evidence aiding decision makers with 
valid information within a limited space. We have given examples and presented ways 
of communicating cost-effectiveness results for e.g. target groups, focusing on how 
information included in a cost-effectiveness league table may be interpreted and 
conveyed and used as a tool in the decision-making process.
PCV83
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O’Mahony R2, Qatami L2, Cutler D1
1National Institute for Health and Clinical Excellence, London, UK; 2Medicines Transparency 
Alliance, Amman, Jordan; 3University of Jordan, Amman, Jordan
OBJECTIVES: The UK’s National Institute for Health and Clinical Excellence (NICE) 
and the Jordan ofﬁ ce of the Medicines Transparency Alliance embarked on a pilot 
project to design an evidence-based guideline for cost-effective pharmacological treat-
ment of essential hypertension in Jordan. The project’s objectives were to directly 
address a major health problem for Jordan by producing a guideline; and to delineate 
the strengths and weaknesses of Jordan’s health care process to allow similar future 
efforts to be planned more efﬁ ciently. METHODS: The pilot spanned a period of 
approximately 8 months. Activities were overseen by local technical and guideline 
development teams, as well as experts from NICE. NICE’s hypertension guidelines 
and economic model were used as a starting point. Parameters in the economic model 
were adjusted according to input and feedback from local experts with regards to 
Jordanian physician and patient practices, resource costs, and quality of life estimates. 
The results of the economic model were integrated with the updated available clinical 
trial literature. RESULTS: The outputs of the economic model were used to inform 
recommendations, in the form of a clinical algorithm. a report of the process and the 
strengths and weaknesses observed was developed, and recommendations for improve-
ments made. CONCLUSIONS: The pilot represented the start of what is intended to 
be a health care process change for the country of Jordan. Issues emerged which can 
inform strategies to ensure a more cohesive and comprehensive health care approach 
